Cancer diagnostics company NeoGenomics beats Q3 estimates on clinical revenue growth

NeoGenomics

28/10/2025 11:12

Overview

NeoGenomics Q3 revenue rises 12% to $188 mln, beating analyst expectations

Net loss for Q3 increases 53% to $27 mln

Adjusted EBITDA for Q3 declines 9% to $12 mln

Outlook

NeoGenomics reaffirms full-year 2025 guidance for revenue, net loss, and adjusted EBITDA

Company expects clinical volume growth to drive Q4 performance and 2026 momentum

Result Drivers

CLINICAL REVENUE GROWTH - Clinical revenue grew 18%, driven by increased test volumes and strategic reimbursement initiatives

NGS REVENUE INCREASE - NGS revenue rose 24% YoY, now accounting for nearly one-third of clinical revenue

OPERATING EXPENSES - Operating expenses rose 12% due to impairment charges and higher compensation costs

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Revenue
Beat
$188 mln
$183.76 mln (14 Analysts)
Q3 Adjusted Net Income
$3.60 mln
Q3 Net Income
-$27 mln
Q3 Adjusted EBITDA
$12.20 mln
Q3 Gross Profit
$80 mln
Q3 Operating Expenses
$107 mln


Analyst Coverage

The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 6 "strong buy" or "buy", 8 "hold" and 1 "sell" or "strong sell"

The average consensus recommendation for the healthcare facilities & services peer group is "buy."

Wall Street's median 12-month price target for Neogenomics Inc is $11.00, about 7.6% above its October 27 closing price of $10.16

The stock recently traded at 64 times the next 12-month earnings vs. a P/E of 32 three months ago

Press Release: ID:nBwnHXK2a

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)